However, there was not concordance between the percentage of clinicians who selected GLP-1 RAs in the CME simulation after feedback (304/435, 69.9%) and the percentage of clinicians using GLP-1 RAs in patients with T2D in the real world who also participated in the CME simulation (69/157, 44%). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.